越南原料药 (API) 市场 – 行业趋势及 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

越南原料药 (API) 市场 – 行业趋势及 2030 年预测

  • Healthcare
  • Published Report
  • Apr 2023
  • Country Level
  • 350 页面
  • 桌子數: 18
  • 图号: 55

Vietnam Active Pharmaceutical Ingredient Api Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2024 –2030
Diagram Market Size (Base Year)
USD MILLION
Diagram Market Size (Forecast Year)
USD 101,174.22
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>越南活性药物成分 (API) 市场,按治疗类别(抗生素、心血管、脂质、降药、传染病、麻醉药、非甾体抗炎药、镇痛药、抗病毒药、皮肤病学、肿瘤学、内分泌学、泌尿学、胃肠病学、眼科学、激素类药物、肌肉松弛剂、帕金森病、牛皮癣、癫痫病、免疫学、血液学、抗肿瘤药、免疫抑制剂等)、类型(创新活性药物成分和通用活性药物成分)、制造商类型(专属制造商和商业制造商)、合成(化学合成和生物技术)、药物类型(处方药和非处方药)、应用(临床、研究)、效力(传统效力活性药物成分和高效活性药物成分)、分子(小分子和大分子)划分分子)、最终用户(制药业、生物技术业、研究和学术机构等)、分销渠道(直接招标、零售销售等)——行业趋势和预测到 2030 年。

越南原料药 (API) 市场分析及规模

活性药物成分 (API) 具有以下特点:对安全有效产品的需求不断增长,这将影响制造商向市场推出新产品,从而增加其需求,并增加对研发的投资,从而促进市场增长。对活性药物成分开发研究的投资不断增加,预计将为活性药物成分 (API) 市场提供各种其他机会。然而,劣质药品和假药的供应以及高昂的制造成本预计将在预测期内抑制市场增长。

越南原料药 (API) 市场越南原料药 (API) 市场

活性药物成分 (API) 市场报告提供了市场份额、新发展和产品线分析的详细信息,国内和本地化市场参与者的影响,分析了新兴收入来源、市场法规变化、产品审批、战略决策、产品发布、地域扩展和市场技术创新方面的机遇。要了解分析和市场情景,请联系我们获取分析师简报。我们的团队将帮助您创建影响收入的解决方案,以实现您的预​​期目标。另一方面,市场参与者的战略举措以及农业领域和食品饮料行业的兴起可能为越南活性药物成分 (API) 市场的增长提供机遇。过度使用磷酸盐产品所带来的风险可能会给越南活性药物成分 (API) 市场带来挑战。越南活性药物成分 (API) 市场有一些最新进展。

预计越南活性药物成分 (API) 市场将在 2023 年至 2030 年的预测期内实现市场增长。Data Bridge Market Research 分析称,在 2023 年至 2030 年的预测期内,该市场的复合年增长率为 8.1%,预计到 2030 年将达到 101,174.22 百万美元。各种慢性疾病患病率的不断上升和老龄化人口的增加是预测期内推动市场需求的主要驱动力。

Data Bridge Market Research 分析,预计到 2030 年,越南活性药物成分 (API) 市场价值将达到 1011.7422 亿美元,复合年增长率为 8.1%。由于慢性病发病率不断上升,抗生素细分市场是市场上最大的产品细分市场,预计这将增加对 API 的需求,并促进越南活性药物成分 (API) 市场的增长。

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021 (可定制为 2015-2020)

定量单位

收入(百万美元)

涵盖的领域

按治疗类别(抗生素、心血管、血脂、降血药、传染病、麻醉药、非甾体抗炎药、镇痛药、抗病毒药、皮肤病学、肿瘤学、内分泌学、泌尿学、胃肠病学、眼科学、激素类药物、肌肉松弛剂、帕金森病、牛皮癣、癫痫病、免疫学、血液学、抗肿瘤药、免疫抑制剂等)、类型(创新活性药物成分和仿制活性药物成分)、制造商类型(专属制造商和商业制造商)、合成(化学合成和生物技术)、药物类型(处方药和非处方药)、应用(临床、研究)、效力(传统活性药物成分和高效活性药物成分)、分子(小分子和大分子)、最终用户(制药业、生物技术业、研究和学术机构等)、分销渠道(直接招标、零售等)

覆盖国家

越南

涵盖的市场参与者

越南活性药物成分 (API) 市场的一些主要参与者包括 Dr. Reddy's Laboratories Ltd.、赛诺菲、辉瑞公司、葛兰素史克公司、Aurobindo Pharma、阿斯利康、Novo Nordisk A/S、Unichem Laboratorie、Jubilant Pharma Limite、MEKOPHA、Lupi、Sun Pharmaceutical Industries Ltd.、Divi's Laboratories Limited、CH Boehringer Sohn AG & Co. K 和 BASF SE 等。

市场定义

在希腊语中,活性药物成分 (API) 的传统单词是 pharmacon 或 pharmakon,象征着一种神奇的物质或药物。ICH Q7 对活性药物成分的描述是“任何用于制造药品的物质或物质组合,当用于生产药品时,即成为活性药物成分。此类物质用于提供药理活性。当将多种 API 添加到药品中时,药品会产生各种治疗活性,可用于治疗各种疾病和控制其症状。少量的活性药物成分即可有效为人体提供治疗效果。活性药物成分在 API 制造过程中发生化学变化,然后以改性形式存在于成品药品中,以提供特定的治疗效果。

越南原料药 (API) 市场动态

本节旨在了解市场驱动因素、机遇、限制因素和挑战。下文将详细讨论所有这些内容:     

驱动程序

各种慢性病患病率不断上升

糖尿病、心血管疾病、呼吸系统疾病等慢性疾病的高发性预计将推动活性药物成分 (API) 市场的发展。慢性疾病的负担正在迅速影响越南、中国、蒙古等世界各地的人口,并恶化人们的健康和生活质量。糖尿病、心脏病、呼吸系统疾病、关节炎、帕金森病、多发性硬化症和阿尔茨海默病等慢性疾病可能导致长期残疾,也会恶化越南人民的健康状况。

在越南,糖尿病的发病率一直以惊人的速度增长,过去10年里发病率翻了一番。糖尿病前期患者的数量也是糖尿病患者数量的三倍。

  • 尽管大多数种族/民族的糖尿病发病率下降,但越南裔美国女性的糖尿病发病率却在上升
  • 研究表明,越南裔美国人的癌症和糖尿病死亡率随时间趋势而增加
  • 每 17 个越南成年人中就有 1 人患有糖尿病(每 15 个男性中就有 1 人,每 20 个女性中就有 1 人)

因此,这意味着随着慢性病患病率的提高,对活性药物成分 (API) 的开发和创新的需求正在增加,从而导致预测期内越南活性药物成分 (API) 市场的增长。

克制

制造成本高

API 制造成本被视为满足 cGMP 以及世界卫生组织 (WHO) GMP 和 SRL 标准的昂贵投资之一。API 生产的制造成本由于以下一些原因而增加:

  • 为了改善生产设施,用先进的技术取代旧的 API 生产技术,对于制造商来说成本可能很高,因为与其他技术相比,先进技术的成本较高
  • 先进的技术需要能够使用这些技术的高素质人才。流程、产品功效档案以及必须满足监管机构要求的安全测试有时对制造商来说是昂贵的,尤其是对那些参与小规模制造的制造商来说
  • 从监管机构获取监管批准的成本被认为是 API 制造成本高的因素之一。监管批准的成本主要对于那些参与生产少量 API 的公司(即小规模制造商)来说很高

因此,高昂的制造成本会成为活性药物成分 (API) 增长的一个制约因素,尤其是对于小规模制造商和新进入者,因为他们必须获得 FDA 批准,并且研发启动成本约为 110 亿美元到 120 亿美元,具体取决于制造商发现了哪些 API,这可能会降低越南活性药物成分 (API) 市场的增长。 

越南原料药 (API) 市场

机会

医疗支出增加

政府不断致力于改善医疗设施,为患者提供更好的医疗设施和治疗。公共和私营部门的公司在改善医疗保健行业、为个人提供健康福利方面都发挥着至关重要的作用。一个国家的总收入水平与该国政府在人口健康方面的支出密切相关。

为了让人们能够获得现有的治疗,政府正致力于增加医疗保健支出。

一个国家的医疗支出越高,该国患病和非手术死亡的几率就越低,这对整个国家的发展起着重要作用。医疗支出的增加使患者能够熟悉他们所需的创新 API 配制的先进和新型药物,以便获得更好的治疗,从而获得更健康的生活。随着全球医疗支出的增加,制造公司也将主动利用先进技术开发 API

挑战

制药行业劳动力短缺

有大量制造公司参与 API 的生产,如今技术不断进步,需要拥有适当技能和技术的劳动力来生产 API。但 API 生产新开发技术的需求不断增加和复杂性不断增加,给制造商带来了挑战。

例如,

  • 根据世界经济论坛灯塔项目,制药公司缺乏熟练劳动力,这为新技术的推广设置了障碍。制药公司与熟练劳动力之间存在差距,而人们并没有因为高科技的增加而得到升级
  • 根据 2022 年 3 月发布的一份报告《越南的招聘挑战和留住员工的潜在激励措施》。外国直接投资公司在越南招聘熟练劳动力方面仍然举步维艰。主要挑战包括缺乏技术基础设施、研发支出、职业和技术技能。缺乏熟练劳动力可能会减缓从劳动密集型产业向高科技产品的经济转型,从而降低越南的竞争力。因此,政府应在教育和工业培训方面进行改革,以满足当前的行业需求

此外,日新月异的技术也给制造商的生产带来了挑战。缺乏熟练的实验室专业人员会导致 API 生产不准确,并使流程繁琐繁琐,这给制造商带来了困难。因此,劳动力短缺对越南活性药物成分 (API) 市场的增长构成了挑战。

最新动态

  • 2021 年 1 月,赛诺菲宣布了欧洲公司的名称 EUROAPI,该公司将生产和商业化活性药物成分。该公司将被视为欧洲最大的 API 生产公司之一。这些 API 将在欧洲以及其他地区销售。这有助于该公司在活性药物成分方面拓展其全球业务,这将在未来增加其市场收入
  • 2020 年 4 月,雷迪博士实验室有限公司收到了美国医疗监管机构颁发的 EIR,即机构检查报告。该公司已收到位于纳尔贡达的活性药物制造单位的 EIR。当美国食品药品监督管理局的检查令人满意且制造厂的设施达到标准时,美国食品药品监督管理局就会收到 EIR。这份 EIR 批准帮助该公司增强了制造设施,这将最终增加其产品产量
  • 2020 年 2 月,赛诺菲宣布了他们的计划,他们将创建一家以生产和销售活性药物成分为基础的欧洲公司。这些 API 将销售给 API 的第三方。该公司已决定,它将与赛诺菲的 API 制造和营销活动一起成为一家独立的公司。该公司背后的动机是减少市场上 API 的短缺。这有助于该公司提高与 API 相关的市场增长,尤其是来自第三方销售的增长

越南原料药 (API) 市场范围

越南活性药物成分 (API) 市场分为十个显著的细分市场,例如治疗类别、类型、制造商类型、合成、效力、药物类型、分子、应用、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略,并确定您的核心应用领域和目标市场的差异。

按治疗类别

  • 抗生素
  • 心血管
  • 降脂药物
  • 传染病
  • 麻药
  • 非甾体抗炎药
  • 镇痛药
  • 抗病毒物质
  • 皮肤科
  • 肿瘤学
  • 内分泌学
  • 泌尿科
  • 胃肠病学
  • 眼科
  • 激素类药物
  • 肌肉松弛剂
  • 帕金森
  • 银屑病
  • 癫痫
  • 免疫学
  • 血液学
  • 抗肿瘤
  • 免疫抑制剂
  • 其他的

依据产品,越南活性药物成分(API)市场细分为抗生素、心血管药物、降脂药物、传染病药物、麻醉药、非甾体抗炎药、镇痛药、抗病毒药、皮肤病学、肿瘤学、内分泌学、泌尿学、胃肠病学、眼科学、激素药物、肌肉松弛剂、帕金森病、牛皮癣、癫痫病、免疫学、血液学、抗肿瘤药、免疫抑制剂和其他越南活性药物成分(API)市场。

按类型

  • 创新活性药物成分
  •  通用活性药物成分

根据类型,越南活性药物成分 (API) 市场分为创新活性药物成分和通用活性药物成分。

按制造商类型

  • 专属制造商
  •  商家制造商

根据制造商类型,越南活性药物成分 (API) 市场分为专属制造商和商业制造商。

通过合成

  • 化学合成
  •  生物技术

根据合成方式,越南活性药物成分 (API) 市场分为化学合成和生物技术。

按效力

  • 传统功效活性药物成分
  •  高效活性药物成分

根据效力,越南活性药物成分 (API) 市场分为传统效力活性药物成分和高效活性药物成分。

按药物类型

  • 处方药
  •  非处方药

根据药品类型,越南活性药物成分 (API) 市场分为处方药和非处方药。

按分子

  • 小分子
  • 大分子

根据分子,越南活性药物成分 (API) 市场分为小分子和大分子。

按应用

  • 临床 
  •  研究

根据应用,越南活性药物成分 (API) 市场分为临床和研究。

按最终用户

  • 制药行业
  •  生物科技产业
  •  研究与学术机构
  •  其他的

根据最终用户,越南活性药物成分 (API) 市场分为制药行业、生物技术行业、研究和学术机构等。

按分销渠道

  • 直接招标
  •  零售销售
  •  其他的

根据分销渠道,越南活性药物成分 (API) 市场分为直接招标、零售和其他。

越南原料药 (API) 市场

越南活性药物成分 (API) 市场区域分析/见解

越南活性药物成分 (API) 市场分为十个显著细分市场,例如治疗类别、类型、制造商类型、合成、效力、药物类型、分子、应用、最终用户和分销渠道。

报告的国家部分还提供了影响单个市场因素和国内市场法规变化,这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外,在对国家数据进行预测分析时,还考虑了磷及其衍生物的存在和可用性以及由于严格法规而面临的挑战。

竞争格局和越南原料药 (API) 市场份额分析

越南活性药物成分 (API) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、业务扩张、服务设施、合作伙伴关系、战略发展、应用优势和技术生命线曲线。以上提供的数据点仅与公司对越南活性药物成分 (API) 市场的关注有关。

越南活性药物成分 (API) 市场的一些主要参与者包括 Dr. Reddy's Laboratories Ltd.、Sanofi、Pfizer Inc.、GSK plc、Aurobindo Pharma、AstraZeneca、Novo Nordisk A/S、Unichem Laboratorie、Jubilant Pharma Limited、MEKOPHAR、Lupin、Sun Pharmaceutical Industries Ltd.、Divi's Laboratories Limited、CH Boehringer Sohn AG & Co. KG 和 BASF SE 等


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 MOLECULE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET TYPE OF END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 CONTACT LIST OF MARKETING PERSONS INVOLVE IN PURCHASE OF ACTIVE PHARMACEUTICAL INGREDIENTS

4.4 PIPELINE ANALYSIS FOR CHILE GASTRIC CANCER TREATMENT MARKET

5 REGULATORY FRAMEWORK

5.1 OVERVIEW

5.2 CURRENT GOODS MANUFACTURING PRACTICES

5.3 REGULATORY REQUIREMENTS FOR REGISTRATION OF API IN VIETNAM

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF VARIOUS CHRONIC DISEASE

6.1.2 INCREASE IN THE AGING POPULATION

6.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING

6.1.4 INCREASING DISEASE AWARENESS AND EDUCATION

6.1.5 PATENT EXPIRY OF BRANDED ACTIVE PHARMACEUTICAL INGREDIENTS (API)

6.2 RESTRAINTS

6.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS

6.2.2 HIGH MANUFACTURING COST

6.2.3 ADVERSE HEALTH EFFECTS OF EXPOSURE TO ACTIVE PHARMACEUTICAL INGREDIENTS (API)

6.3 OPPORTUNITIES

6.3.1 COLLABORATION AND ACQUISITION AMONG THE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS

6.3.2 INCREASING HEALTHCARE EXPENDITURE

6.3.3 RISING INVESTMENT IN RESEARCH REGARDING THE DEVELOPMENT OF ACTIVE PHARMACEUTICAL INGREDIENTS (API)

6.3.4 SOARING NUMBER OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS

6.4 CHALLENGES

6.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19

6.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES

7 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC CLASS

7.1 OVERVIEW

7.2 ANTIBIOTIC

7.3 CARDIOVASCULAR

7.4 LIPID LOWERING DRUGS

7.5 INFECTIOUS DISEASE

7.6 ANESTHETIC

7.7 NSAIDS

7.8 ANALGESIC

7.9 ANTIVIRAL

7.1 DERMATOLOGY

7.11 ONCOLOGY

7.12 ENDOCRINOLOGY

7.13 UROLOGY

7.14 GASTROENTEROLOGY

7.15 OPHTHALMOLOGY

7.16 HORMONAL AGENTS

7.17 MUSCLE RELAXANT

7.18 PARKINSON

7.19 PSORIASIS

7.2 EPILEPTIC

7.21 IMMUNOLOGY

7.22 HEMATOLOGY

7.23 ANTINEOPLASTIC

7.24 IMMUNOSUPPRESSIVE AGENTS

7.25 OTHERS

8 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE

8.1 OVERVIEW

8.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

8.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

9 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER

9.1 OVERVIEW

9.2 CAPTIVE MANUFACTURERS

9.2.1 CAPTIVE INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

9.2.2 CAPTIVE GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

9.3 MERCHANT MANUFACTURERS

9.3.1 MERCHANT INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

9.3.2 MERCHANT GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

10 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS

10.1 OVERVIEW

10.2 CHEMICAL SYNTHETIC

10.2.1 SAXAGLIPTIN

10.2.2 ENOXAPARIN SODIUM

10.2.3 RUFINAMIDE

10.2.4 TAMOXIFEN

10.2.5 ARTEMISININ

10.2.6 LOSARTAN POTASSIUM

10.2.7 NAPROXEN

10.2.8 IBUPROFEN

10.2.9 ACETAMINOPHEN

10.2.10 SODIUM CHLORIDE

10.2.11 OTHERS

10.3 BIOTECH

10.3.1 MONOCLONAL ANTIBODIES

10.3.2 CYTOKINES

10.3.3 HORMONES & GROWTH FACTORS

10.3.4 BLOOD FACTORS

10.3.5 RECOMBINANT VACCINES

10.3.6 THERAPEUTIC ENZYMES BIOTECH

11 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY

11.1 OVERVIEW

11.2 TRADITIONAL POTENCY ACTIVE PHARMACEUTICAL INGREDIENT

11.3 HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENT

12 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, TYPE OF DRUG

12.1 OVERVIEW

12.2 PRESCRIPTION DRUGS

12.3 OVER-THE-COUNTER DRUGS

13 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, MOLECULE

13.1 OVERVIEW

13.2 SMALL MOLECULE

13.3 LARGE MOLECULE

14 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, APPLICATION

14.1 OVERVIEW

14.2 CLINICAL

14.3 RESEARCH

15 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY END USER

15.1 OVERVIEW

15.2 PHARMACEUTICAL INDUSTRIES

15.2.1 LARGE

15.2.2 MEDIUM

15.2.3 SMALL

15.3 BIOTECHNOLOGY INDUSTRIES

15.3.1 LARGE

15.3.2 MEDIUM

15.3.3 SMALL

15.4 RESEARCH AND ACADEMIC INSTITUTES

15.5 OTHERS

16 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDERS

16.3 RETAIL SALES

16.4 OTHERS

17 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: VIETNAM

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 PFIZER, INC.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 PRODUCT PORTFOLIO

19.1.4 RECENT DEVELOPMENTS

19.2 MEKOPHAR

19.2.1 COMPANY SNAPSHOT

19.2.2 RECENT FINANCIALS

19.2.3 PRODUCT PORTFOLIO

19.2.4 RECENT DEVELOPMENT

19.3 ASTRAZENECA

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 PRODUCT PORTFOLIO

19.3.4 RECENT DEVELOPMENT

19.4 DIVI’S LABORATORIES LIMITED

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 PRODUCT PORTFOLIO

19.4.4 RECENT DEVELOPMENTS

19.5 SANOFI

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENTS

19.6 DR. REDDY’S LABORATORY LTD.

19.6.1 COMPANY SNAPSHOT

19.6.2 RECENT FINANCIALS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT

19.7 AUROBINDO PHARMA

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENT

19.8 BASF SE

19.8.1 COMPANY SNAPSHOT

19.8.2 RECENT FINANCIALS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENT

19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENTS

19.1 GSK PLC

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE FINANCIALS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 JUBILANT PHARMOVA LIMITED

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENT

19.12 LUPIN

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENTS

19.13 NOVO NORDISK A/S

19.13.1 COMPANY SNAPSHOT

19.13.2 REVENUE ANALYSIS

19.13.3 PRODUCT PORTFOLIO

19.13.4 RECENT DEVELOPMENT

19.14 SUN PHARMACEUTICAL INDUSTRIES LTD.

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENT

19.15 UNICHEM LABORATORIES

19.15.1 COMPANY SNAPSHOT

19.15.2 REVENUE ANALYSIS

19.15.3 PRODUCT PORTFOLIO

19.15.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

表格列表

TABLE 1 BELOW PROVIDED TABLE IS PROVIDING DATA OF DIFFERENT APIS WITH THEIR THERAPEUTIC APPLICATIONS UNDER THE CLINICAL TRIAL:

TABLE 2 BELOW ARE SOME MANUFACTURERS WHO ARE INVOLVED IN THE PRODUCTION OF ACTIVE PHARMACEUTICAL INGREDIENTS (API):

TABLE 3 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC CLASS, 2021-2030 (USD MILLION)

TABLE 4 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 5 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2021-2030 (USD MILLION)

TABLE 6 VIETNAM CAPTIVE MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2021-2030 (USD MILLION)

TABLE 7 VIETNAM MERCHANT MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2021-2030 (USD MILLION)

TABLE 8 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2021-2030 (USD MILLION)

TABLE 9 VIETNAM CHEMICAL SYNTHETIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2021-2030 (USD MILLION)

TABLE 10 VIETNAM BIOTECH IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2021-2030 (USD MILLION)

TABLE 11 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2021-2030 (USD MILLION)

TABLE 12 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2021-2030 (USD MILLION)

TABLE 13 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2021-2030 (USD MILLION)

TABLE 14 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2021-2030 (USD MILLION)

TABLE 15 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 16 VIETNAM PHARMACEUTICAL INDUSTRIES IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SIZE, 2021-2030 (USD MILLION)

TABLE 17 VIETNAM BIOTRCHNOLOGY INDUSTRIES IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SIZE, 2021-2030 (USD MILLION)

TABLE 18 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

图片列表

FIGURE 1 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION

FIGURE 2 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DATA TRIANGULATION

FIGURE 3 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DROC ANALYSIS

FIGURE 4 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MULTIVARIATE MODELLING

FIGURE 7 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MARKET TYPE OF END USER COVERAGE GRID

FIGURE 11 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF VARIOUS CHRONIC DISORDERS AND THE RISING AGEING POPULATION IS DRIVING THE VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN THE FORECAST PERIOD OF 2023 TO 2030

FIGURE 13 ANTIBIOTIC SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN 2023 TO 2030

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET

FIGURE 15 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC CLASS, 2022

FIGURE 16 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC CLASS, 2023-2030 (USD MILLION)

FIGURE 17 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC CLASS, CAGR (2023-2030)

FIGURE 18 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC CLASS, LIFELINE CURVE

FIGURE 19 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2022

FIGURE 20 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 21 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 22 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURER, 2022

FIGURE 24 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURER, 2023-2030 (USD MILLION)

FIGURE 25 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURER, CAGR (2023-2030)

FIGURE 26 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURER, LIFELINE CURVE

FIGURE 27 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2022

FIGURE 28 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2023-2030 (USD MILLION)

FIGURE 29 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, CAGR (2023-2030)

FIGURE 30 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, LIFELINE CURVE

FIGURE 31 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2022

FIGURE 32 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2023-2030 (USD MILLION)

FIGURE 33 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, CAGR (2023-2030)

FIGURE 34 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, LIFELINE CURVE

FIGURE 35 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG , 2022

FIGURE 36 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG , 2023-2030 (USD MILLION)

FIGURE 37 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG , CAGR (2023-2030)

FIGURE 38 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG , LIFELINE CURVE

FIGURE 39 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2022

FIGURE 40 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2023-2030 (USD MILLION)

FIGURE 41 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, CAGR (2023-2030)

FIGURE 42 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, LIFELINE CURVE

FIGURE 43 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY APPLICATION, 2022

FIGURE 44 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 45 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 46 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 47 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY END USER, 2022

FIGURE 48 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY END USER 2023-2030 (USD MILLION)

FIGURE 49 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY END USER, CAGR (2023-2030)

FIGURE 50 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY END USER, LIFELINE CURVE

FIGURE 51 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 52 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 53 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 54 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 55 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY SHARE 2022 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Vietnam active pharmaceutical ingredients (API) market size will be worth USD 101,174.22 million by 2030.
The growth rate of the Vietnam active pharmaceutical ingredients (API) market is 8.1% in the forecast by 2030.
Major companies in the Vietnam active pharmaceutical ingredients (API) market are Dr. Reddy’s Laboratories Ltd., Sanofi, Pfizer Inc, GSK plc, Aurobindo Pharma, AstraZeneca, Novo Nordisk A/S, Unichem Laboratories, Jubilant Pharma Limite, MEKOPHA, Lupi, etc.
Therapeutic class, type, type of manufacturer, synthesis, potency, type of drug, molecule, application, end user, and distribution channel are the factors on which the Vietnam active pharmaceutical ingredients (API) market research is based.
The high prevalence of chronic diseases such as diabetes, cardiovascular disease, respiratory diseases, and others are the growth drivers of the Vietnam active pharmaceutical ingredients (API) market.